CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, June 12, 2026

In accordance with the provisions of article 226 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

INSIDE INFORMATION

Pharma Mar, S.A. announces top-line results from its Phase III LAGOON trial evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second line) metastatic small cell lung cancer (SCLC), which did not meet its primary endpoint of Overall Survival (OS) compared with control arm, nor did the exploratory combination with irinotecan. Safety for lurbinectedin monotherapy is better compared to the control group.

The LAGOON study targeted a different population in a different setting of SCLC than the IMforte Phase III trial first line maintenance with atezolizumab (Tecentriq®) and does not impact lurbinectedin approval in the first-line maintenance setting.

Please find attached press release that will be distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

Press release

PharmaMar Reports Update on Phase III LAGOON Trial in Second Line for Small Cell Lung Cancer

Madrid, June 12th, 2026.- PharmaMar (MSE: PHM), announced top-line results from its Phase III LAGOON trial evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second line) metastatic small cell lung cancer (SCLC), which did not meet its primary endpoint of Overall Survival (OS) compared with control arm, nor did the exploratory combination with irinotecan. Safety for lurbinectedin monotherapy is better compared to the control group.

The LAGOON study targeted a different population in a different setting of SCLC than the IMforte Phase III trial first line maintenance with atezolizumab (Tecentriq®) and does not impact lurbinectedin approval in the first-line maintenance setting.

The full European Commission (EC) and U.S. approval of lurbinectedin is based on the Phase III IMforte trial, which evaluated lurbinectedin in combination with atezolizumab as first-line maintenance treatment for patients with extensive-stage SCLC. In the IMforte trial, the lurbinectedin and atezolizumab combination demonstrated a statistically significant improvement in the primary endpoints of OS and progression-free survival (PFS), as assessed by an independent review facility, compared to treatment with atezolizumab alone. The lurbinectedin and atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to atezolizumab maintenance therapy alone.

PharmaMar and its partners will share the results with regulatory bodies as needed at appropriate time.

Key Results from the Phase III LAGOON Trial

The LAGOON trial included a broader patient population than the Phase 2 pivotal trial that supported the second-line approval, including patients with a history of CNS involvement.

The outcome of this trial may be impacted by the unexpected OS outperformance of the control arm by 30% (topotecan mOS 10.8) when compared to most recent phase III trials (topotecan 8.3m,)[1] in this setting.

[1] RESILIENT all with data since 2018

Trial Population	Lurbinectedin monotherapy Median OS	Lurbinectedin + irinotecan Median OS	Control Median OS	HR (95% CI) Lurbinectedin vs Control	HR (95% CI) Lurbinectedin+irinotecan vs Control
Overall	8.7 (n=240)	10.9 (n=242)	10.7 (n=242)	1.190 (0.959, 1.476)	0.902 (0.729, 1.115)
Without CNS metastases	9.6 (n=182)	11.1 (n=189)	10.7 (n=186)	1.106 (0.875, 1.398)	0.922 (0.729, 1.166)
With CNS metastases	7.1 (n=58)	10.5 (n= 53)	10.3 (n=56)	1.791 (1.162, 2.760)	1.107 (0.724, 1.692)

The overall safety profile for lurbinectedin was favorable relative to the control arm. Treatment-related adverse events (TRAE) were 78.5% with lurbinectedin, 95% with lurbinectedin + irinotecan, and 93.8% with the control arm. TRAEs Grade ≥ 3 were 35% with lurbinectedin, 62.6% with lurbinectedin + irinotecan, and 64.4% with the control arm.

We expect to submit the results to a medical meeting for presentation.

PharmaMar would like to thank all the patients, their families, and the medical staff involved in the study.

PharmaMar Call for Investors and Analysts

PharmaMar management will host a conference call and webcast for investors and analysts on June 15th, 2026, at 14:00 CEST (08:00 AM, New York time) as follows. The numbers to connect to the teleconference are +1 646 233 4753 (from USA or Canada), +34 91 901 16 44 (from Spain) and +44 20 3936 2999 (other countries). Participants access code: 825412.

Interested parties can also follow the conference call live via the following link: https://streamstudio.world-television.com/1052-1618-43506/en

The recording of the teleconference will be available for thirty days and it can be accessed on PharmaMar's website by visiting the Events Calendar section of the Company's website www.pharmamar.com.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself. In addition, Zepzelca® (lurbinectedin), in the US and other countries; and Aplidin® (plitidepsin), in Australia, each with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: PM534 and PM54.

Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi) and contract-manufacturing (CDMO) of oligonucleotides. For more information, please visit: www.pharmamar.com .

About Zepzelca®

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:
Lara Vadillo – Communications director lvadillo@pharmamar.com
Phone: +34 918466000

Capital Markets & Investor Relations:
José Luis Moreno– VP Capital Markets & Investor Relations
Natalia Amo – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at **www.pharmamar.com**